KY-1044
Based on 1 Customer Validation
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.51%
- No. CAS: 2489390-15-8
- Peso molecular:146.5 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Human IgG1 kappa
Human
ICOS/CD278
KY-1044 (Alomfilimab; SAR 445256; 0-100ng/mL; 4 hours) causes human natural killer (NK) cells expressing hICOS (5:1 effector:target cell ratio) to induce potent ADCC-mediated killing (EC50=5.6 pmol/L)[1].
KY-1044 significantly induces the luciferase signal (EC50 of 0.15 nmol/L). A similar EC50 is obtained against mouse ICOS (0.53 nmol/L), rat ICOS (0.48 nmol/L), or cynomolgus monkey ICOS (0.22 nmol/L)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In syngeneic mouse tumor models, KY-1044 depletes ICOShigh Treg and increases the intratumoral TEff:Treg ratio, resulting in increased secretion of IFNγ and TNFα by TEff cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8- to 10-week-old wild-type female Balb/C or C57BL/6J mice with A20 cells[1]
-
Dosage:200 μg (10 mg/kg)
-
Administration:IP; twice a week for 3 weeks starting from 6 days following tumor cell implantation
-
Result:Triggered an antitumor response, with more than 90% of the mice being free from measurable disease at the end of the study (day 42).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized ICOS Protein, Human can bind Alomfilimab. The EC50 for this effect is 11.35 ng/mL. -
Chemical Information
-
No. CAS 2489390-15-8
-
Appearance Liquid
-
Peso molecular 146.5 kDa
-
Color Colorless to light yellow
-
SMILES
[KY-1044]
-
Synonyms
Alomfilimab; SAR 445256
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)